| Literature DB >> 29346042 |
Hedy L Kindler1, Nofisat Ismaila1, Samuel G Armato1, Raphael Bueno1, Mary Hesdorffer1, Thierry Jahan1, Clyde Michael Jones1, Markku Miettinen1, Harvey Pass1, Andreas Rimner1, Valerie Rusch1, Daniel Sterman1, Anish Thomas1, Raffit Hassan1.
Abstract
Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .Entities:
Mesh:
Year: 2018 PMID: 29346042 PMCID: PMC8058628 DOI: 10.1200/JCO.2017.76.6394
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544